ClinicalTrials.gg
RecruitingNCT01619917Updated May 14, 2026

The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars

An interventional study of Fractional Vascular Laser in Burn Scar, sponsored by University of Manitoba. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University of Manitoba · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

While the literature tends to support the use of laser therapy in the management of burn scars, there is a definite lack of appropriately powered, randomized controlled trials. Laser therapy can be quite expensive when compared to other treatment modalities for burn scars, and while promising, its true usefulness has yet to be conclusively demonstrated. For this reason, our assessing the effects of fractional vascular lasers on burn scars. It has been hypothesized that the fractional vascular lasers work on mature scars to decrease scar formation, and the fractional laser works on scar that is quiescent to promote remodelling. The retexturing/ resurfacing of the laser theoretically can decrease the visibility of the mesh pattern created by meshed split thickness skin graft).

Objective:

To determine the benefit of fractional vascular laser treatment in improving burn scar height, texture, vascularity and pliability in late burn scars.

02

Conditions studied

  • Burn Scar

Browse trials for

Keywords

  • burn
  • scar
  • laser
  • fractional
  • vascular
03

In context

Burns

905 studies on the registry are indexed under Burns; 164 are open to participants now.

This study's planned enrollment of 6 is below the median of 40 across 663 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 89 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • living in Winnipeg
  • burn scar 6-12 months old
  • Fitzpatrick skin type I-III
  • thermal burn scar on trunk or extremities

Exclusion criteria

Exclusion Criteria:

  • open wound
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
6 participants (estimated)

Study arms

  • Active comparator
    Proximal

    location of the scar proximal to heart

    Device: Fractional Vascular Laser

  • Experimental
    Distal

    location of scar distal to heart

    Device: Fractional Vascular Laser

Interventions

  • DeviceFractional Vascular Laser

    laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result

06

What researchers measure

Primary outcomes

  1. reduction in scar appearance

    examine with modified Vancouver Scar Scale

    Time frame: every 3 weeks to 15 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jun 2028 and a completion of Jul 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2012
First posted
Jun 14, 2012
Start
Nov 1, 2012
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jul 1, 2028
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01619917
Responsible party
Dr. Sarvesh Logsetty (Principal Investigator, University of Manitoba) — Principal investigator
First posted
Jun 14, 2012
Start date
Nov 1, 2012
Primary completion
Jun 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
May 14, 2026

Study contacts

Justin Gawaziuk, MSc
Contact
jgawaziuk@hsc.mb.ca
2047893669
S Logsetty, MD
principal investigator · University of Manitoba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion